← Leaderboards
Lin Zhang
University Of Southern California
$14,677,842
Attributed
$16,635,655
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,635,655 · 8
By mechanism
R01$16,635,655 · 8
Top collaborators
- Zaneta Nikolovska-Coleska5 shared
- Jian Yu3 shared
Most similar at University Of Southern California
Same institution · by research overlap
- Yehuda Ben-Zion$14,075,960
- Paolo Zanardi$775,000
- Meghan S Miller$644,077
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingMalignant NeoplasmsCancer CellCellsResistanceApoptosisTumorProtein FamilyResponseColorectal CancerCessation Of LifeCancer EtiologyProteinsPathway InteractionsAntineoplastic AgentsMutationIn VivoGeneticCell DeathBaseCancer TherapyApoptoticMitochondriaInsight
Grant awards (46)
BET degraders for improving colorectal cancer therapy$438,915
R01 · FY2025 · CA · contact PI
Targeting defective necroptosis in colorectal cancer$476,741
R01 · FY2024 · CA · contact PI
BET degraders for improving colorectal cancer therapy$422,894
R01 · FY2024 · CA · contact PI
Role of necroptosis in colorectal cancer therapy$461,812
R01 · FY2023 · CA · contact PI
Targeting defective necroptosis in colorectal cancer$449,762
R01 · FY2023 · CA · contact PI
BET degraders for improving colorectal cancer therapy$418,169
R01 · FY2023 · CA · contact PI
Role of necroptosis in colorectal cancer therapy$436,808
R01 · FY2022 · CA · contact PI
Targeting defective necroptosis in colorectal cancer$430,693
R01 · FY2022 · CA · contact PI
BET degraders for improving colorectal cancer therapy$416,526
R01 · FY2022 · CA · contact PI
Novel Mcl-1 inhibitors for overcoming therapeutic resistance in colorectal cancer$516,652
R01 · FY2021 · CA
Role of necroptosis in colorectal cancer therapy$445,723
R01 · FY2021 · CA · contact PI
Targeting defective necroptosis in colorectal cancer$443,378
R01 · FY2021 · CA · contact PI
BET degraders for improving colorectal cancer therapy$381,024
R01 · FY2021 · CA · contact PI
Novel Mcl-1 inhibitors for overcoming therapeutic resistance in colorectal cancer$516,593
R01 · FY2020 · CA
Targeting defective necroptosis in colorectal cancer$461,400
R01 · FY2020 · CA · contact PI
Role of necroptosis in colorectal cancer therapy$445,723
R01 · FY2020 · CA · contact PI
Role of Mcl-1 degradation in colorecal cancer therapy$344,446
R01 · FY2020 · CA · contact PI
Novel Mcl-1 inhibitors for overcoming therapeutic resistance in colorectal cancer$501,374
R01 · FY2019 · CA
Role of necroptosis in colorectal cancer therapy$445,723
R01 · FY2019 · CA · contact PI
Role of Mcl-1 degradation in colorecal cancer therapy$334,332
R01 · FY2019 · CA · contact PI
Novel Mcl-1 inhibitors for overcoming therapeutic resistance in colorectal cancer$516,449
R01 · FY2018 · CA
Role of Mcl-1 degradation in colorecal cancer therapy$344,895
R01 · FY2018 · CA · contact PI
Novel Mcl-1 inhibitors for overcoming therapeutic resistance in colorectal cancer$529,087
R01 · FY2017 · CA
Role of Mcl-1 degradation in colorecal cancer therapy$345,110
R01 · FY2017 · CA · contact PI
Bid-mediated killing of oncogenic stem cells in chemoprevention$319,550
R01 · FY2017 · CA · contact PI
Role of Mcl-1 degradation in colorecal cancer therapy$345,319
R01 · FY2016 · CA · contact PI
Bid-mediated killing of oncogenic stem cells in chemoprevention$319,550
R01 · FY2016 · CA · contact PI
Bid-mediated killing of oncogenic stem cells in chemoprevention$319,550
R01 · FY2015 · CA · contact PI
Bid-mediated killing of oncogenic stem cells in chemoprevention$309,209
R01 · FY2014 · CA · contact PI
PUMA-mediated apoptosis in human cancer cells$254,099
R01 · FY2014 · CA · contact PI
Bid-mediated killing of oncogenic stem cells in chemoprevention$316,438
R01 · FY2013 · CA · contact PI
PUMA-mediated apoptosis in human cancer cells$246,317
R01 · FY2013 · CA · contact PI
PUMA-mediated apoptosis in human cancer cells$262,120
R01 · FY2012 · CA · contact PI
SMAC in chemoprevention of colon cancer$263,626
R01 · FY2011 · CA · contact PI
PUMA-mediated apoptosis in human cancer cells$262,197
R01 · FY2011 · CA · contact PI
SMAC in chemoprevention of colon cancer$272,080
R01 · FY2010 · CA · contact PI
PUMA-mediated apoptosis in human cancer cells$270,385
R01 · FY2010 · CA · contact PI
SMAC in chemoprevention of colon cancer$272,374
R01 · FY2009 · CA · contact PI
SMAC in Chemoprevention of Colon Cancer$197,708
R01 · FY2009 · CA · contact PI
SMAC in chemoprevention of colon cancer$272,659
R01 · FY2008 · CA · contact PI
Apoptotic Response to DNA Damage Initiated by PUMA$259,785
R01 · FY2008 · CA · contact PI
SMAC in chemoprevention of colon cancer$272,935
R01 · FY2007 · CA · contact PI
Apoptotic Response to DNA Damage Initiated by PUMA$259,785
R01 · FY2007 · CA · contact PI
Apoptotic Response to DNA Damage Initiated by PUMA$267,544
R01 · FY2006 · CA · contact PI
Apoptotic Response to DNA Damage Initiated by PUMA$273,983
R01 · FY2005 · CA
Apoptotic Response to DNA Damage Initiated by PUMA$274,213
R01 · FY2004 · CA